AI Business | Jul 4, 2026

Analysis

• Anthropic's decision to develop drugs of its own — announced alongside its Claude Science workbench — moves a frontier lab from selling AI tools into becoming an end-market drug developer, and puts it in the unusual position of selling software to firms it may now compete with. It sharpens a contest already joined by OpenAI, Amazon, and Google, all of which field life-sciences platforms, over whether labs capture value as arms dealers to pharma or as drug originators themselves.
• Canada Pension Plan Investment Board's $1.75 billion into EQT Corp.'s EdgeConneX buildout channels long-duration institutional capital toward more than 10 gigawatts of new data-center capacity even as near-term chip equities fell on the same session — the SOX index dropped 5.4%, with AMD, TSMC, and Broadcom each off more than 2%. Pension and infrastructure investors are underwriting the multi-year layer of power and real estate that AI compute depends on while public markets reprice the accelerator names.
• Both of the day's stories show AI value migrating toward the edges of the stack rather than the model itself: Anthropic reaching downstream into drug end-markets and a $1.75 billion pension commitment reaching upstream into physical compute capacity. On an otherwise quiet news day, the money and strategy on display are moving to the infrastructure floor and the application ceiling, not the frontier-model middle.

RESEARCH & MODELS

• SCIUPDATEThe Verge | Anthropic wants to develop its own drugs | At an "AI for Science" event this week, Anthropic launched Claude Science, an "AI workbench for scientists" that consolidates fragmented tools and datasets and generates figures, and said it would go further by developing drugs of its own. Head of life sciences Eric Kauderer-Abrams said the company will focus on treatments for "neglected" diseases. Anthropic's planned move is one of the most direct public attempts by a major frontier AI company to develop drugs itself, placing it in the position of selling software to potentially competing drugmakers alongside life-sciences efforts from OpenAI, Amazon, and Google.

COMPUTING & INFRASTRUCTURE

• DCBloomberg | CPP Invests $1.75 Billion in EQT's AI Infrastructure Buildout | Canada Pension Plan Investment Board will invest $1.75 billion to support EQT Corp.'s artificial-intelligence infrastructure buildout, it announced Friday. The buildout is led by EQT subsidiary EdgeConneX, which plans to develop more than 10 gigawatts of additional data centers.

MARKETS

3 Jul 2026 close | Retrieved 3 Jul 22:00 UTC | Yahoo Finance

AI Equities (1D) | Nvidia 194.83 USD -1.4% | Microsoft 390.49 USD +1.6% | Alphabet 359.91 USD -0.4% | Meta 583 USD -4.9% | Amazon 242.67 USD +0.4% | Palantir 129.30 USD +2.8%

Semiconductors (1D) | AMD 518 USD -4.3% | TSMC 434.16 USD -2.3% | Broadcom 360.45 USD -2.4% | ARM 315.28 USD -6.6% | Super Micro 27.22 USD -1.6%

AI Infrastructure (1D) | CoreWeave 81.75 USD -4.6%

Indices (1D) | NASDAQ 25,833 -0.8% | SOX 12,626 -5.4%

Coverage: 3 Jul 01:00 – 4 Jul 01:00 UTC